Spark Therapeutics announced new preclinical data for SPK-3006, an investigational liver-directed adeno-associated viral (AAV) gene therapy for Pompe disease. This was announced during the late-breakling session of the International Annual Congress of the World Muscle Society. This is a one-time investigational gene therapy that is engineered to use the liver to express the needed enzyme. Positive results have been seen at the 10-month point in mouse studies.
advocacy awards Awareness Breakthrough therapy designation business CAP chaperone clinical trials CORD COVID-19 Emma Rooney ERT Extraordinary Measures Fabry FDA fundraising Gaucher gene therapy genetics getting treated grants Health Canada home infusions IND Int'l Pompe Day IPA law living with Pompe meetings Muscular Dystrophy Canada MyNormal newborn screening NIH Orphan Drug Framework Orphanet portraits preclinical pregnancy privacy Rare Disease Rare Disease Day research respite substrate reduction therapy video